Aurinia Pharmaceuticals
AUPH
14.70
-0.19
-1.28%
Aurinia Pharmaceuticals
US · AUPH
#2749 by market cap
Listed 1970
14.70
-0.19
-1.28%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.5 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 67.14% -0.46pp
- Institutions
- 341 -2
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund44.56%
Hedge Fund8.99%
VC/PE Fund6.68%
Public Company4.38%
Individual/Insider2.17%
Government Pension Fund0.79%
Private Company0.73%
Insurance Company0.58%
Family Office/Trust0.17%
Bank/Investment Bank0.16%
Other30.96%
Top holders as of 2026-06-30
Tang Capital Management, LLC
9.73% · 13.04M sh
BlackRock
6.41% · 8.59M sh
ILJIN SNT Co., Ltd
3.72% · 4.99M sh
Goldman Sachs Asset Management, L.P.
3.65% · 4.88M sh
New Enterprise Associates, Inc.
2.96% · 3.97M sh
Two Sigma Investments, LP
2.59% · 3.47M sh
Arrowstreet Capital, Limited Partnership
2.44% · 3.26M sh
State Street Global Advisors
1.93% · 2.59M sh
Morgan Stanley
1.55% · 2.06M sh
Marshall Wace LLP
1.53% · 2.04M sh
LSV Asset Management
1.35% · 1.81M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 27 buys · 23 sells
| Name | Role | Stake |
|---|---|---|
| Peter Greenleaf | Consultant | 0.78% |
| Matthew Donley | Former Chief Operating Officer | 0.33% |
| Joseph Miller | Former Chief Financial Officer | 0.26% |
| Stephen Robertson | Chief Legal Officer, Corporate Secretary & Chief Compliance Officer | 0.23% |
| David R. Jayne | Former Director | 0.03% |
| Gregory Keenan | Former Chief Medical Officer | 0.02% |
| Jeffrey Bailey | Independent Director | 0.02% |
| Craig Johnson | Lead Independent Director | 0.01% |
| Jill Leversage | Former Director | 0.01% |
| Karen Smith | Former Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-09 | Stephen Robertson | Chief Legal Officer, Corporate Secretary & Chief Compliance Officer | Open Market Disposition | -11,939 | $15.95 |
| 2026-08-20 | Stephen Robertson | Chief Legal Officer, Corporate Secretary & Chief Compliance Officer | Open Market Disposition | -20,975 | $16.97 |
| 2026-06-04 | Gregory Keenan | Former Chief Medical Officer | Intent to Sell (Form 144) | -9,593 | $16.52 |
| 2026-06-03 | Tina Nova | Independent Director | Other Derivative Acquisition | +23,931 | $15.67 |
| 2026-06-03 | Craig Johnson | Lead Independent Director | Other Derivative Acquisition | +23,931 | $15.67 |
| 2026-06-03 | Jeffrey Bailey | Independent Director | Other Derivative Acquisition | +23,931 | $15.67 |
| 2026-06-03 | Gregory Keenan | Former Chief Medical Officer | Intent to Sell (Form 144) | -25,000 | $16.34 |
| 2026-06-03 | Kathleen Goetz | -- | Other Derivative Acquisition | +23,931 | $15.67 |
| 2026-06-01 | Tang Capital Management, LLC | -- | Open Market Acquisition | +814,606 | $15.28–15.35 |
| 2026-06-01 | Tang Capital Management, LLC | -- | Other Derivative Acquisition | +10,000 | $15.00 |
| 2026-06-01 | Gregory Keenan | Former Chief Medical Officer | Intent to Sell (Form 144) | -25,000 | $2,164.00 |
| 2026-05-17 | Michael Hearne | Chief Financial Officer | Other Acquisition | +116,144 | -- |
| 2026-05-17 | Michael Hearne | Chief Financial Officer | Other Derivative Acquisition | +70,230 | $15.28 |
| 2026-05-17 | Ryan Cole | Chief Operating Officer | Other Acquisition | +116,144 | -- |
| 2026-05-17 | Ryan Cole | Chief Operating Officer | Other Derivative Acquisition | +70,230 | $15.28 |
| 2026-05-17 | Stephen Robertson | Chief Legal Officer, Corporate Secretary & Chief Compliance Officer | Other Acquisition | +115,541 | -- |
| 2026-05-10 | Peter Greenleaf | Consultant | Intent to Sell (Form 144) | -3,136,201 | $15.84 |
| 2026-05-10 | Joseph Miller | Former Chief Financial Officer | Intent to Sell (Form 144) | -500,503 | $15.84 |
| 2026-03-05 | Gregory Keenan | Former Chief Medical Officer | Sale to Issuer | -8,069 | $14.32 |
| 2026-03-02 | Tang Capital Management, LLC | -- | Open Market Acquisition | +898,400 | $13.90–14.33 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.
Aurinia Pharmaceuticals discussion 0 comments